1 / 6

Lysosomal Storage Disorder Therapeutics Pipeline | Clinical Trials & Results

Lysosomal Storage Disorders Pipeline Market Analysis and Forecast for the Drug Candidates in the Last Stage of Development.

NidhiNehani
Télécharger la présentation

Lysosomal Storage Disorder Therapeutics Pipeline | Clinical Trials & Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lysosomal Storage Disorder Therapeutics Pipeline has Maximum Drugs Being Developed as Gene Therapy

  2. Lysosomal Storage Disorder Therapeutics According to a new research report “Lysosomal Storage Disorder Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Lysosomal Storage Disorder currently exhibits a strong pipeline with 74 drug candidates. Browse Report Description at: https://www.psmarketresearch.com/market-analysis/lysosomal-storage-disorders-pipeline-analysis Lysosomal Storage Disorder therapeutics pipeline in 2017 The study analyzed that the lysosomal storage disorder therapeutics pipeline comprises approximately 74 drug candidates in different stages of development.

  3. Lysosomal Storage Disorder Therapeutics Insights on pipeline segments According to the research findings, most of the drug candidates for lysosomal storage disorder pipeline are being developed to be administered by intravenous route. CHART technology platform for lysosomal storage disorder drug development Amicus Therapeutics, Inc. is using chaperone advanced replacement therapy (CHART) technology platform for the development of their drug candidates for the treatment of Fabry disease, a type of lysosomal storage disorder. In a chaperone-advanced replacement therapy, a unique pharmacological chaperone, binds to the infused therapeutic enzyme, stabilizing the enzyme in its properly folded and active form. This proposed CHART mechanism may allow for enhanced tissue uptake, greater lysosomal activity, more reduction of storage material, and lower immunogenicity compared to ERT alone.

  4. Lysosomal Storage Disorder Therapeutics Natural Sources used for the development of drugs in the Lysosomal Storage Disorder Therapeutics Pipeline The research also found that various companies use natural sources for the development of lysosomal storage disorder therapeutics pipeline. ProtalixBioTherapeutics, Inc. is developing their drug candidates, obtained from a natural source, for the treatment of Fabry disease. Some of the other key players developing drugs for the treatment of lysosome storage disorder include GlaxoSmithKline plc, Sanofi Genzyme, Amicus Therapeutics, Inc. and others.

  5. Lysosomal Storage Disorder Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/lysosomal-storage-disorders-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related